利妥昔单抗治疗儿童原发性肾病综合征机制的研究进展

doi:10.3760/cma.j.issn.1007-1245.2022.10.034

摘要/Abstract

摘要： 原发性肾病综合征是儿童常见的肾脏疾病，长期应用糖皮质激素及免疫抑制剂治疗带来了诸多不良反应。利妥昔单抗是一种针对CD20的人鼠嵌合单克隆抗体，其作为一种生物制剂于2002年首次应用于肾病领域的治疗，具有疗程短、依从性强、缓解率高、不良反应小等优点，是一种极具治疗潜力的新型药物。但目前对利妥昔单抗治疗原发性肾病综合征的研究多集中在其有效性和安全性上，对其治疗肾病综合征的具体机制尚不清楚。本文就近年来对利妥昔单抗治疗肾病综合征的相关机制研究进行了总结，以期更好为临床实践提供依据。

关键词: 儿童, 肾病综合征, 利妥昔单抗

Abstract: Primary nephrotic syndrome is a common kidney disease in children, and long-term treatment with glucocorticoids and immunosuppressive agents brings many adverse effects. Rituximab, a chimeric human/mouse monoclonal anti-CD20 antibody, was first used as a biologic agent in the treatment of nephropathy in 2002. As a novel drug with great therapeutic potential, it is chiefly characterized by its short treatment course, high compliance, high remission rate, and slight adverse effects. However, the current research on rituximab for primary nephrotic syndrome is mostly focused on its efficacy and safety, and the specific mechanism of its treatment for nephrotic syndrome is not clear enough. This paper summarizes the mechanism of rituximab in the treatment of nephrotic syndrome in recent years, hoping it could be exploited in clinical practice.

Key words: Children, Nephrotic syndrome, Rituximab

姚超, 段培锋. 利妥昔单抗治疗儿童原发性肾病综合征机制的研究进展[J]. 国际医药卫生导报, 2022, 28(10): 1472-1476.

Yao Chao, Duan Peifeng. Advances in the mechanism of rituximab for the treatment of primary nephrotic syndrome in children[J]. International Medicine and Health Guidance News, 2022, 28(10): 1472-1476.

参考文献

[1] Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children[J].Lancet,2018,392(10141):61-74. DOI:10.1016/S0140-6736(18)30536-1.

[2] Eddy AA, Symons JM. Nephrotic syndrome in childhood[J].Lancet,2003,362(9384):629-639. DOI:10.1016/S0140-6736(03)14184-0.

[3] Trautmann A, Vivarelli M, Samuel S, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome[J].Pediatr Nephrol,2020,35(8):1529-1561. DOI:10.1007/s00467-020-04519-1.

[4] Cattran DC, Alexopoulos E, Heering P, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome : workshop recommendations[J].Kidney Int,2007,72(12):1429-1447. DOI:10.1038/sj.ki.5002553.

[5] Iijima K, Sako M, Nozu K. Rituximab for nephrotic syndrome in children[J].ClinExp Nephrol,2017,21(2):193-202. DOI:10.1007/s10157-016-1313-5.

[6] Kim JH, Park E, Hyun HS, et al. Long-term repeated rituximab treatment for childhood steroid-dependent nephrotic syndrome[J].Kidney Res Clin Pract,2017,36(3):257-263. DOI:10.23876/j.krcp.2017.36.3.257.

[7] Nakagawa T, Shiratori A, Kawaba Y, et al. Efficacy of rituximab therapy against intractable steroid-resistant nephrotic syndrome[J].Pediatr Int,2016,58(10):1003-1008. DOI:10.1111/ped.12948.

[8] Kopp JB, Anders HJ, Susztak K, et al. Podocytopathies[J].Nat Rev Dis Primers,2020,6(1):68. DOI:10.1038/s41572-020-0196-7.

[9] Yu SM, Nissaisorakarn P, Husain I, et al. Proteinuric kidney diseases: a podocyte's slit diaphragm and cytoskeleton approach[J].Front Med (Lausanne),2018,5:221. DOI:10.3389/fmed.2018.00221.

[10] Artelt N, Ludwig TA, Rogge H, et al. The role of palladin in podocytes[J].J Am Soc Nephrol,2018,29(6):1662-1678. DOI:10.1681/ASN.2017091039.

[11] Heinz LX, Baumann CL, Köberlin MS, et al. The lipid-modifying enzyme SMPDL3B negatively regulates innate immunity[J].Cell Rep,2015,11(12):1919-1928. DOI:10.1016/j.celrep.2015.05.006.

[12] Watanabe S, Tsugawa K, Tsuruga K, et al. Urinary excretion of sphingomyelinasephosphodiesterase acid-like 3b in children with intractable nephrotic syndrome[J].Pediatr Int,2017,59(10):1112-1115. DOI:10.1111/ped.13355.

[13] Ahmad A, Mitrofanova A, Bielawski J, et al. Sphingomyelinase-like phosphodiesterase 3b mediates radiation-induced damage of renal podocytes[J].FASEB J,2017,31(2):771-780. DOI:10.1096/fj.201600618R.

[14] Fornoni A, Sageshima J, Wei C, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis[J].SciTransl Med,2011,3(85):85ra46. DOI:10.1126/scitranslmed.3002231.

[15] Takahashi Y, Ikezumi Y, Saitoh A. Rituximab protects podocytes and exerts anti-proteinuric effects in rat adriamycin-induced nephropathy independent of B-lymphocytes[J].Nephrology (Carlton),2017,22(1):49-57. DOI:10.1111/nep.12737.

[16] Kim AH, Chung JJ, Akilesh S, et al. B cell-derived IL-4 acts on podocytes to induce proteinuria and foot process effacement[J].JCI Insight,2017,2(21):e81836. DOI:10.1172/jci.insight.81836.

[17] Dossier C, Jamin A, Deschênes G. Idiopathic nephrotic syndrome: the EBV hypothesis[J].Pediatr Res,2017,81(1-2):233-239. DOI:10.1038/pr.2016.200.

[18] Colucci M, Carsetti R, Cascioli S, et al. B cell phenotype in pediatric idiopathic nephrotic syndrome[J].Pediatr Nephrol,2019,34(1):177-181. DOI:10.1007/s00467- 018-4095-z.

[19] Kidoguchi K, Katsuya H, Ureshino H, et al. Concomitant nephrotic syndrome with diffuse large B-cell lymphoma: a case report[J].Tohoku J Exp Med,2020,252(2):153-157. DOI:10.1620/tjem.252.153.

[20] Pavlasova G, Mraz M. The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy[J].Haematologica,2020,105(6):1494-1506. DOI:10.3324/haematol.2019.243543.

[21] Pérez-Callejo D, González-Rincón J, Sánchez A, et al. Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas[J].Cancer Treat Rev,2015,41(8):680-689. DOI:10.1016/j.ctrv.2015.05.007.

[22] Harris DP, Haynes L, Sayles PC, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells[J].Nat Immunol,2000,1(6):475-482. DOI:10.1038/82717.

[23] McDonald BS, Jones J, Rustin M. Rituximab as a treatment for severe atopic eczema: failure to improve in three consecutive patients[J].ClinExp Dermatol,2016,41(1):45-47. DOI:10.1111/ced.12691.

[24] Ma XL, Lin QY, Wang L, et al. Rituximab prevents and reverses cardiac remodeling by depressing B cell function in mice[J].Biomed Pharmacother,2019,114:108804. DOI:10.1016/j.biopha.2019.108804.

[25] Jamin A, Berthelot L, Couderc A, et al. Autoantibodies against podocytic UCHL1 are associated with idiopathic nephrotic syndrome relapses and induce proteinuria in mice[J].J Autoimmun,2018,89:149-161. DOI:10.1016/j.jaut.2017.12.014.

[26] Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function[J].Lancet,1974,2(7880):556-560. DOI:10.1016/s0140-6736(74)91880-7.

[27] Chebotareva N, Bobkova I, Lysenko L. T regulatory cells in renal tissue of patients with nephroticsyndrome[J].Pediatr Int,2020,62(7):884-885. DOI:10.1111/ped.14294.

[28] Bhatia D, Sinha A, Hari P, et al. Rituximab modulates T- and B-lymphocyte subsets and urinary CD80 excretion in patients with steroid-dependent nephrotic syndrome[J].Pediatr Res,2018,84(4):520-526. DOI:10.1038/s41390-018-0088-7.

[29] Kanai T, Shiraishi H, Yamagata T, et al. Th2 cells predominate in idiopathic steroid-sensitive nephrotic syndrome[J].ClinExp Nephrol,2010,14(6):578-583. DOI:10.1007/s10157-010-0330-z.

[30] Chan CY, Liu ID, Resontoc LP, et al. T lymphocyte activation markers as predictors of responsiveness to rituximab among patients with FSGS[J].Clin J Am Soc Nephrol,2016,11(8):1360-1368. DOI:10.2215/CJN.11941115.

[31] Li YY, Wei SG, Zhao X, et al. Th17/Treg cell expression in children with primary nephritic syndrome and the effects of ox-LDL on Th17/Tregcells[J].Genet Mol Res,2016,15(2):27323155. DOI:10.4238/gmr.15027669.

[32] Wang L, Li Q, Wang L, et al. The role of Th17/IL-17 in the pathogenesis of primary nephrotic syndrome in children[J].Kidney Blood Press Res,2013,37(4-5):332-345. DOI:10.1159/000350161.

[33] Garin EH, Mu W, Arthur JM, et al. Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis[J].Kidney Int,2010,78(3):296-302. DOI:10.1038/ki.2010.143.

[34] Roccatello D, Sciascia S, Di Simone D, et al. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: a prospective study and a review of the literature[J].Autoimmun Rev,2016,15(6):529-538. DOI:10.1016/j.autrev.2016.02.014.

[35] van de Veerdonk FL, Lauwerys B, Marijnissen RJ, et al. The anti-CD20 antibody rituximab reduces the Th17 cell response[J].Arthritis Rheum,2011,63(6):1507-1516. DOI:10.1002/art.30314.

[36] Ciccia F, Guggino G, Rizzo A, et al. Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome[J].Rheumatology (Oxford),2014,53(7):1313-1320. DOI:10.1093/rheumatology/keu004.

[37] Eggleton P, Bremer E. Direct and indirect rituximab-induced T cell depletion: comment on the article by Mélet et Al[J].Arthritis Rheumatol,2014,66(4):1053. DOI:10.1002/art.38347.

[38] Holley JE, Bremer E, Kendall AC, et al. CD20+inflammatory T-cells are present in blood and brain of multiple sclerosis patients and can be selectively targeted for apoptotic elimination[J].MultSclerRelat Disord,2014,3(5):650-658. DOI:10.1016/j.msard.2014.06.001.